Because SMARCA4 deficiency is common in small cell ovarian cancer (82), Burkitt lymphoma (83) and pediatric medulloblastoma (84), among other tumor types (85), ATRi monotherapy may be effective and specific against other SMARCA4-deficient cancer cells with minimal undesirable effects. This evidence concerns the gene SMARCA4 and Burkitt lymphoma.